ID   S5A2_HUMAN              Reviewed;         254 AA.
AC   P31213; B2RE87; Q2M1R4; Q9BYE6;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   15-MAR-2017, entry version 162.
DE   RecName: Full=3-oxo-5-alpha-steroid 4-dehydrogenase 2;
DE            EC=1.3.1.22 {ECO:0000269|PubMed:10898110};
DE   AltName: Full=5 alpha-SR2;
DE   AltName: Full=SR type 2;
DE   AltName: Full=Steroid 5-alpha-reductase 2;
DE            Short=S5AR 2;
DE   AltName: Full=Type II 5-alpha reductase;
GN   Name=SRD5A2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1944596; DOI=10.1038/354159a0;
RA   Andersson S., Berman D.M., Jenkins E.P., Russell D.W.;
RT   "Deletion of steroid 5 alpha-reductase 2 gene in male
RT   pseudohermaphroditism.";
RL   Nature 354:159-161(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1505484; DOI=10.1210/endo.131.3.1505484;
RA   Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y.,
RA   Bachvarov D., Leblanc G., Durocher F., Paquet N.;
RT   "Structure of human type II 5 alpha-reductase gene.";
RL   Endocrinology 131:1571-1573(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-89.
RC   TISSUE=Liver tumor;
RA   Schupp I.;
RL   Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-49; LEU-89 AND
RP   VAL-113.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-89.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-67.
RC   TISSUE=Placenta;
RA   Nakanishi J., Hibino T.;
RT   "Transcription of type II 5 alpha-reductase is up-regulated by SRY in
RT   human dermal papilla cells.";
RL   Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   VARIANT PPSH TRP-246.
RX   PubMed=1522235; DOI=10.1172/JCI115954;
RA   Thigpen A.E., Davis D.L., Milatovich A., Mendonca B.B.,
RA   Imperato-Mcginley J., Griffin J.E., Francke U., Wilson J.D.,
RA   Russell D.W.;
RT   "Molecular genetics of steroid 5 alpha-reductase 2 deficiency.";
RL   J. Clin. Invest. 90:799-809(1992).
RN   [10]
RP   VARIANT PPSH MET-157 DEL.
RX   PubMed=7554313; DOI=10.1111/j.1365-2265.1995.tb01913.x;
RA   Boudon C., Lobaccaro J.-M., Lumbroso S., Ogur G., Ocal G., Belon C.,
RA   Sultan C.;
RT   "A new deletion of the 5-alpha-reductase type 2 gene in a Turkish
RT   family with 5-alpha-reductase deficiency.";
RL   Clin. Endocrinol. (Oxf.) 43:183-188(1995).
RN   [11]
RP   VARIANTS PPSH ASP-115; SER-183 AND TRP-246.
RX   PubMed=8626825; DOI=10.1210/jcem.81.5.8626825;
RA   Cai L.-Q., Zhu Y.-S., Katz M.D., Herrera C., Baez J.,
RA   DeFillo-Ricart M., Shackleton C.H.L., Imperato-McGinley J.;
RT   "5-alpha-reductase-2 gene mutations in the Dominican Republic.";
RL   J. Clin. Endocrinol. Metab. 81:1730-1735(1996).
RN   [12]
RP   VARIANT PPSH GLN-55.
RX   PubMed=8768837; DOI=10.1210/jcem.81.8.8768837;
RA   Hochberg Z., Chayen R., Reiss N., Falik Z., Makler A., Munichor M.,
RA   Farkas A., Goldfarb H., Ohana N., Hiort O.;
RT   "Clinical, biochemical, and genetic findings in a large pedigree of
RT   male and female patients with 5-alpha-reductase 2 deficiency.";
RL   J. Clin. Endocrinol. Metab. 81:2821-2827(1996).
RN   [13]
RP   VARIANT PPSH LYS-200.
RX   PubMed=9208814; DOI=10.1136/mp.50.1.51;
RA   Anwar R., Gilbey S.G., New J.P., Markham A.F.;
RT   "Male pseudohermaphroditism resulting from a novel mutation in the
RT   human steroid 5 alpha-reductase type 2 gene (SRD5A2).";
RL   Mol. Pathol. 50:51-52(1997).
RN   [14]
RP   VARIANT PPSH THR-228.
RX   PubMed=9843052;
RX   DOI=10.1002/(SICI)1096-8628(19981116)80:3<269::AID-AJMG18>3.3.CO;2-K;
RA   Nordenskjold A., Magnus O., Aagenaes O., Knudtzon J.;
RT   "Homozygous mutation (A228T) in the 5-alpha-reductase type 2 gene in a
RT   boy with 5-alpha-reductase deficiency: genotype-phenotype
RT   correlations.";
RL   Am. J. Med. Genet. 80:269-272(1998).
RN   [15]
RP   VARIANTS PPSH SER-196 AND ARG-231.
RX   PubMed=9745434; DOI=10.1210/jcem.83.9.5125;
RA   Nordenskjold A., Ivarsson S.-A.;
RT   "Molecular characterization of 5-alpha-reductase type 2 deficiency and
RT   fertility in a Swedish family.";
RL   J. Clin. Endocrinol. Metab. 83:3236-3238(1998).
RN   [16]
RP   VARIANT THR-49, AND POLYMORPHISM.
RX   PubMed=10501358; DOI=10.1016/S0140-6736(98)11282-5;
RA   Makridakis N.M., Ross R.K., Pike M.C., Crocitto L.E., Kolonel L.N.,
RA   Pearce C.L., Henderson B.E., Reichardt J.K.V.;
RT   "Association of mis-sense substitution in SRD5A2 gene with prostate
RT   cancer in African-American and Hispanic men in Los Angeles, USA.";
RL   Lancet 354:975-978(1999).
RN   [17]
RP   VARIANTS PPSH ASP-85; ASP-115; ARG-212; TYR-245 AND GLN-246.
RX   PubMed=10718838; DOI=10.1046/j.1365-2265.2000.00941.x;
RA   Vilchis F., Mendez J.P., Canto P., Lieberman E., Chavez B.;
RT   "Identification of missense mutations in the SRD5A2 gene from patients
RT   with steroid 5alpha-reductase 2 deficiency.";
RL   Clin. Endocrinol. (Oxf.) 52:383-387(2000).
RN   [18]
RP   VARIANTS PPSH ASP-197 AND ARG-212.
RX   PubMed=10999800; DOI=10.1210/jcem.85.9.6786;
RA   Chavez B., Valdez E., Vilchis F.;
RT   "Uniparental disomy in steroid 5-alpha-reductase 2 deficiency.";
RL   J. Clin. Endocrinol. Metab. 85:3147-3150(2000).
RN   [19]
RP   VARIANTS ARG-5; LEU-30; ARG-48; THR-49; THR-51; LEU-89; MET-187;
RP   LEU-194; GLN-227 AND LEU-234, FUNCTION, CATALYTIC ACTIVITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10898110; DOI=10.1097/00008571-200007000-00004;
RA   Makridakis N.M., di Salle E., Reichardt J.K.;
RT   "Biochemical and pharmacogenetic dissection of human steroid 5 alpha-
RT   reductase type II.";
RL   Pharmacogenetics 10:407-413(2000).
RN   [20]
RP   VARIANT LEU-89.
RX   PubMed=11927504;
RA   Pearce C.L., Makridakis N.M., Ross R.K., Pike M.C., Kolonel L.N.,
RA   Henderson B.E., Reichardt J.K.V.;
RT   "Steroid 5-alpha reductase type II V89L substitution is not associated
RT   with risk of prostate cancer in a multiethnic population study.";
RL   Cancer Epidemiol. Biomarkers Prev. 11:417-418(2002).
RN   [21]
RP   VARIANT MICROPENIS GLN-227, AND VARIANT LEU-89.
RX   PubMed=12843198; DOI=10.1210/jc.2002-021415;
RA   Sasaki G., Ogata T., Ishii T., Kosaki K., Sato S., Homma K.,
RA   Takahashi T., Hasegawa T., Matsuo N.;
RT   "Micropenis and the 5alpha-reductase-2 (SRD5A2) gene: mutation and
RT   V89L polymorphism analysis in 81 Japanese patients.";
RL   J. Clin. Endocrinol. Metab. 88:3431-3436(2003).
RN   [22]
RP   VARIANT THR-49, AND LACK OF ASSOCIATION WITH PROSTATE CANCER.
RX   PubMed=14560315; DOI=10.1038/sj.ejhg.5201101;
RA   Loukola A., Chadha M., Penn S.G., Rank D., Conti D.V., Thompson D.,
RA   Cicek M., Love B., Bivolarevic V., Yang Q., Jiang Y., Hanzel D.K.,
RA   Dains K., Paris P.L., Casey G., Witte J.S.;
RT   "Comprehensive evaluation of the association between prostate cancer
RT   and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.";
RL   Eur. J. Hum. Genet. 12:321-332(2004).
RN   [23]
RP   VARIANTS PPSH ASP-115 AND TRP-246.
RX   PubMed=15528927; DOI=10.1159/000081893;
RA   Fernandez-Cancio M., Rodo J., Andaluz P., Martinez de Osaba M.J.,
RA   Rodriguez-Hierro F., Esteban C., Carrascosa A., Audi L.;
RT   "Clinical, biochemical and morphologic diagnostic markers in an infant
RT   male pseudohermaphrodite patient with compound heterozygous mutations
RT   (G115D/R246W) in SRD5A2 gene.";
RL   Horm. Res. 62:259-264(2004).
RN   [24]
RP   VARIANTS PPSH TRP-145; LEU-181; SER-196; PHE-235 AND GLN-246, AND
RP   VARIANTS THR-49 AND LEU-89.
RX   PubMed=16181229; DOI=10.1111/j.1365-2265.2005.02348.x;
RA   Nicoletti A., Baldazzi L., Balsamo A., Barp L., Pirazzoli P.,
RA   Gennari M., Radetti G., Cacciari E., Cicognani A.;
RT   "SRD5A2 gene analysis in an Italian population of under-masculinized
RT   46,XY subjects.";
RL   Clin. Endocrinol. (Oxf.) 63:375-380(2005).
RN   [25]
RP   VARIANTS PPSH ARG-126; ARG-158; SER-183; SER-196; ASP-207 AND TRP-246,
RP   AND VARIANTS THR-49 AND LEU-89.
RX   PubMed=15770495; DOI=10.1007/s00109-005-0651-7;
RA   Hackel C., Oliveira L.E., Ferraz L.F., Tonini M.M., Silva D.N.,
RA   Toralles M.B., Stuchi-Perez E.G., Guerra-Junior G.;
RT   "New mutations, hotspots, and founder effects in Brazilian patients
RT   with steroid 5alpha-reductase deficiency type 2.";
RL   J. Mol. Med. 83:569-576(2005).
RN   [26]
RP   VARIANT PPSH ARG-123.
RX   PubMed=16098368; DOI=10.1016/j.urology.2005.02.021;
RA   Bahceci M., Ersay A.R., Tuzcu A., Hiort O., Richter-Unruh A.,
RA   Gokalp D.;
RT   "A novel missense mutation of 5-alpha reductase type 2 gene (SRD5A2)
RT   leads to severe male pseudohermaphroditism in a Turkish family.";
RL   Urology 66:407-410(2005).
CC   -!- FUNCTION: Converts testosterone (T) into 5-alpha-
CC       dihydrotestosterone (DHT) and progesterone or corticosterone into
CC       their corresponding 5-alpha-3-oxosteroids. It plays a central role
CC       in sexual differentiation and androgen physiology.
CC       {ECO:0000269|PubMed:10898110}.
CC   -!- CATALYTIC ACTIVITY: A 3-oxo-5-alpha-steroid + NADP(+) = a 3-oxo-
CC       Delta(4)-steroid + NADPH. {ECO:0000269|PubMed:10898110}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.9 uM for testosterone (at pH 6.0)
CC         {ECO:0000269|PubMed:10898110};
CC         KM=8 uM for NADPH (at pH 6.0) {ECO:0000269|PubMed:10898110};
CC         Vmax=1.9 nmol/min/mg enzyme with testosterone as substrate with
CC         NADPH as cofactor (at pH 6.0) {ECO:0000269|PubMed:10898110};
CC       pH dependence:
CC         Optimally active at acidic pHs.;
CC   -!- SUBCELLULAR LOCATION: Microsome membrane; Multi-pass membrane
CC       protein. Endoplasmic reticulum membrane {ECO:0000305}; Multi-pass
CC       membrane protein {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Expressed in high levels in the prostate and
CC       many other androgen-sensitive tissues.
CC   -!- POLYMORPHISM: Individuals with Thr-49 have an increased risk of
CC       prostate cancer (PubMed:10501358). The enzyme with Thr-49 has a
CC       higher in vitro V(max) than the Ala-49 enzyme (PubMed:10501358).
CC       {ECO:0000269|PubMed:10501358}.
CC   -!- DISEASE: Pseudovaginal perineoscrotal hypospadias (PPSH)
CC       [MIM:264600]: A form of male pseudohermaphroditism in which 46,XY
CC       males show ambiguous genitalia at birth, including perineal
CC       hypospadias and a blind perineal pouch, and develop
CC       masculinization at puberty. The name of the disorder stems from
CC       the finding of a blind-ending perineal opening resembling a vagina
CC       and a severely hypospadiac penis with the urethra opening onto the
CC       perineum. {ECO:0000269|PubMed:10718838,
CC       ECO:0000269|PubMed:10999800, ECO:0000269|PubMed:1522235,
CC       ECO:0000269|PubMed:15528927, ECO:0000269|PubMed:15770495,
CC       ECO:0000269|PubMed:16098368, ECO:0000269|PubMed:16181229,
CC       ECO:0000269|PubMed:7554313, ECO:0000269|PubMed:8626825,
CC       ECO:0000269|PubMed:8768837, ECO:0000269|PubMed:9208814,
CC       ECO:0000269|PubMed:9745434, ECO:0000269|PubMed:9843052}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the steroid 5-alpha reductase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/srd5a2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=5-alpha reductase entry;
CC       URL="https://en.wikipedia.org/wiki/5_alpha_reductase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M74047; AAA60586.1; -; mRNA.
DR   EMBL; AB047857; BAB40419.1; -; Genomic_DNA.
DR   EMBL; EF560740; ABQ59050.1; -; mRNA.
DR   EMBL; AY884245; AAW56942.1; -; Genomic_DNA.
DR   EMBL; AK316597; BAG38184.1; -; mRNA.
DR   EMBL; CH471053; EAX00478.1; -; Genomic_DNA.
DR   EMBL; BC112252; AAI12253.1; -; mRNA.
DR   EMBL; BC113641; AAI13642.1; -; mRNA.
DR   EMBL; L03843; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS74503.1; -.
DR   PIR; A49169; A49169.
DR   RefSeq; NP_000339.2; NM_000348.3.
DR   UniGene; Hs.458345; -.
DR   ProteinModelPortal; P31213; -.
DR   IntAct; P31213; 1.
DR   BindingDB; P31213; -.
DR   ChEMBL; CHEMBL1856; -.
DR   DrugBank; DB00548; Azelaic Acid.
DR   DrugBank; DB01126; Dutasteride.
DR   DrugBank; DB01216; Finasteride.
DR   DrugBank; DB00421; Spironolactone.
DR   GuidetoPHARMACOLOGY; 2633; -.
DR   iPTMnet; P31213; -.
DR   PhosphoSitePlus; P31213; -.
DR   BioMuta; SRD5A2; -.
DR   DMDM; 401056; -.
DR   PeptideAtlas; P31213; -.
DR   PRIDE; P31213; -.
DR   DNASU; 6716; -.
DR   Ensembl; ENST00000622030; ENSP00000477587; ENSG00000277893.
DR   GeneID; 6716; -.
DR   KEGG; hsa:6716; -.
DR   UCSC; uc032nip.2; human.
DR   CTD; 6716; -.
DR   DisGeNET; 6716; -.
DR   GeneCards; SRD5A2; -.
DR   H-InvDB; HIX0030017; -.
DR   HGNC; HGNC:11285; SRD5A2.
DR   MalaCards; SRD5A2; -.
DR   MIM; 264600; phenotype.
DR   MIM; 607306; gene.
DR   neXtProt; NX_P31213; -.
DR   Orphanet; 753; 46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency.
DR   Orphanet; 1331; Familial prostate cancer.
DR   PharmGKB; PA36113; -.
DR   HOVERGEN; HBG003402; -.
DR   InParanoid; P31213; -.
DR   KO; K12344; -.
DR   OrthoDB; EOG091G0KU4; -.
DR   PhylomeDB; P31213; -.
DR   BioCyc; MetaCyc:HS00619-MONOMER; -.
DR   BRENDA; 1.3.1.22; 2681.
DR   BRENDA; 1.3.99.5; 2681.
DR   Reactome; R-HSA-193048; Androgen biosynthesis.
DR   ChiTaRS; SRD5A2; human.
DR   GeneWiki; SRD5A2; -.
DR   GenomeRNAi; 6716; -.
DR   PRO; PR:P31213; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   CleanEx; HS_SRD5A2; -.
DR   Genevisible; P31213; HS.
DR   GO; GO:0070852; C:cell body fiber; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0003865; F:3-oxo-5-alpha-steroid 4-dehydrogenase activity; IBA:GO_Central.
DR   GO; GO:0033218; F:amide binding; IEA:Ensembl.
DR   GO; GO:0047751; F:cholestenone 5-alpha-reductase activity; IEA:UniProtKB-EC.
DR   GO; GO:0009917; F:sterol 5-alpha reductase activity; IDA:UniProtKB.
DR   GO; GO:0030283; F:testosterone dehydrogenase [NAD(P)] activity; IDA:UniProtKB.
DR   GO; GO:0006702; P:androgen biosynthetic process; IBA:GO_Central.
DR   GO; GO:0008209; P:androgen metabolic process; IDA:UniProtKB.
DR   GO; GO:0018879; P:biphenyl metabolic process; IEA:Ensembl.
DR   GO; GO:0060348; P:bone development; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:UniProtKB.
DR   GO; GO:0018894; P:dibenzo-p-dioxin metabolic process; IEA:Ensembl.
DR   GO; GO:0030540; P:female genitalia development; IBA:GO_Central.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0021854; P:hypothalamus development; IEA:Ensembl.
DR   GO; GO:0030539; P:male genitalia development; IBA:GO_Central.
DR   GO; GO:0008584; P:male gonad development; IMP:UniProtKB.
DR   GO; GO:0018963; P:phthalate metabolic process; IEA:Ensembl.
DR   GO; GO:0042448; P:progesterone metabolic process; IBA:GO_Central.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032354; P:response to follicle-stimulating hormone; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   GO; GO:0048545; P:response to steroid hormone; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0006706; P:steroid catabolic process; IEA:Ensembl.
DR   GO; GO:0061370; P:testosterone biosynthetic process; IDA:UniProtKB.
DR   InterPro; IPR016636; 3-oxo-5-alpha-steroid_4-DH.
DR   InterPro; IPR001104; 3-oxo-5_a-steroid_4-DH_C.
DR   Pfam; PF02544; Steroid_dh; 1.
DR   PIRSF; PIRSF015596; 5_alpha-SR2; 1.
DR   PROSITE; PS50244; S5A_REDUCTASE; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Differentiation; Disease mutation;
KW   Endoplasmic reticulum; Membrane; Microsome; NADP; Oxidoreductase;
KW   Polymorphism; Pseudohermaphroditism; Reference proteome;
KW   Sexual differentiation; Transmembrane; Transmembrane helix.
FT   CHAIN         1    254       3-oxo-5-alpha-steroid 4-dehydrogenase 2.
FT                                /FTId=PRO_0000213676.
FT   TRANSMEM      8     28       Helical. {ECO:0000255}.
FT   TRANSMEM     72     92       Helical. {ECO:0000255}.
FT   TRANSMEM    146    166       Helical. {ECO:0000255}.
FT   TRANSMEM    206    226       Helical. {ECO:0000255}.
FT   VARIANT       5      5       C -> R (no effect on affinity for
FT                                testosterone; no effect on affinity for
FT                                NADPH; no effect on Vmax).
FT                                {ECO:0000269|PubMed:10898110}.
FT                                /FTId=VAR_077546.
FT   VARIANT      30     30       P -> L (increased affinity for
FT                                testosterone; increased affinity for
FT                                NADPH; decreased Vmax).
FT                                {ECO:0000269|PubMed:10898110}.
FT                                /FTId=VAR_077547.
FT   VARIANT      48     48       P -> R (increased affinity for
FT                                testosterone; increased affinity for
FT                                NADPH; decreased Vmax).
FT                                {ECO:0000269|PubMed:10898110}.
FT                                /FTId=VAR_077548.
FT   VARIANT      49     49       A -> T (increased affinity for
FT                                testosterone; no effect on affinity for
FT                                NADPH; increased Vmax; no effect on
FT                                affinity for testosterone when associated
FT                                with L-89; no effect on affinity for
FT                                NADPH when associated with L-89;
FT                                increased Vmax when associated with L-89;
FT                                dbSNP:rs9282858).
FT                                {ECO:0000269|PubMed:10501358,
FT                                ECO:0000269|PubMed:10898110,
FT                                ECO:0000269|PubMed:14560315,
FT                                ECO:0000269|PubMed:15770495,
FT                                ECO:0000269|PubMed:16181229,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_013104.
FT   VARIANT      51     51       A -> T (no effect on affinity for
FT                                testosterone; increased affinity for
FT                                NADPH; decreased Vmax).
FT                                {ECO:0000269|PubMed:10898110}.
FT                                /FTId=VAR_077549.
FT   VARIANT      55     55       L -> Q (in PPSH).
FT                                {ECO:0000269|PubMed:8768837}.
FT                                /FTId=VAR_013105.
FT   VARIANT      85     85       G -> D (in PPSH).
FT                                {ECO:0000269|PubMed:10718838}.
FT                                /FTId=VAR_013130.
FT   VARIANT      89     89       V -> L (no effect on affinity for
FT                                testosterone; no effect on affinity for
FT                                NADPH; decreased Vmax; no effect on
FT                                affinity for testosterone when associated
FT                                with T-49; no effect on affinity for
FT                                NADPH when associated with T-49;
FT                                increased Vmax when associated with T-49;
FT                                decreased affinity for testosterone when
FT                                associated with M-187; increased affinity
FT                                for NADPH when associated with M-187;
FT                                decreased Vmax when associated with M-
FT                                187; no effect on affinity for
FT                                testosterone when associated with L-234;
FT                                increased affinity for NADPH when
FT                                associated with L-234; decreased Vmax
FT                                when associated with L-234;
FT                                dbSNP:rs523349).
FT                                {ECO:0000269|PubMed:10898110,
FT                                ECO:0000269|PubMed:11927504,
FT                                ECO:0000269|PubMed:12843198,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:15770495,
FT                                ECO:0000269|PubMed:16181229,
FT                                ECO:0000269|Ref.3, ECO:0000269|Ref.4}.
FT                                /FTId=VAR_013131.
FT   VARIANT     113    113       L -> V (in dbSNP:rs28383048).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_022302.
FT   VARIANT     115    115       G -> D (in PPSH).
FT                                {ECO:0000269|PubMed:10718838,
FT                                ECO:0000269|PubMed:15528927,
FT                                ECO:0000269|PubMed:8626825}.
FT                                /FTId=VAR_013106.
FT   VARIANT     123    123       G -> R (in PPSH).
FT                                {ECO:0000269|PubMed:16098368}.
FT                                /FTId=VAR_025854.
FT   VARIANT     126    126       Q -> R (in PPSH).
FT                                {ECO:0000269|PubMed:15770495}.
FT                                /FTId=VAR_025855.
FT   VARIANT     145    145       R -> W (in PPSH).
FT                                {ECO:0000269|PubMed:16181229}.
FT                                /FTId=VAR_025851.
FT   VARIANT     157    157       Missing (in PPSH).
FT                                {ECO:0000269|PubMed:7554313}.
FT                                /FTId=VAR_013107.
FT   VARIANT     158    158       G -> R (in PPSH).
FT                                {ECO:0000269|PubMed:15770495}.
FT                                /FTId=VAR_025856.
FT   VARIANT     181    181       P -> L (in PPSH).
FT                                {ECO:0000269|PubMed:16181229}.
FT                                /FTId=VAR_025852.
FT   VARIANT     183    183       G -> S (in PPSH).
FT                                {ECO:0000269|PubMed:15770495,
FT                                ECO:0000269|PubMed:8626825}.
FT                                /FTId=VAR_013108.
FT   VARIANT     187    187       T -> M (no effect on affinity for
FT                                testosterone; increased affinity for
FT                                NADPH; decreased Vmax; decreased affinity
FT                                for testosterone when associated with L-
FT                                89; increased affinity for NADPH when
FT                                associated with L-89; decreased Vmax when
FT                                associated with L-89).
FT                                {ECO:0000269|PubMed:10898110}.
FT                                /FTId=VAR_077550.
FT   VARIANT     194    194       F -> L (no effect on affinity for
FT                                testosterone; increased affinity for
FT                                NADPH; increased Vmax).
FT                                {ECO:0000269|PubMed:10898110}.
FT                                /FTId=VAR_077551.
FT   VARIANT     196    196       G -> S (in PPSH).
FT                                {ECO:0000269|PubMed:15770495,
FT                                ECO:0000269|PubMed:16181229,
FT                                ECO:0000269|PubMed:9745434}.
FT                                /FTId=VAR_013109.
FT   VARIANT     197    197       E -> D (in PPSH).
FT                                {ECO:0000269|PubMed:10999800}.
FT                                /FTId=VAR_013110.
FT   VARIANT     200    200       E -> K (in PPSH).
FT                                {ECO:0000269|PubMed:9208814}.
FT                                /FTId=VAR_013132.
FT   VARIANT     203    203       G -> S (in dbSNP:rs9332961).
FT                                /FTId=VAR_059791.
FT   VARIANT     207    207       A -> D (in PPSH).
FT                                {ECO:0000269|PubMed:15770495}.
FT                                /FTId=VAR_025857.
FT   VARIANT     212    212       P -> R (in PPSH).
FT                                {ECO:0000269|PubMed:10718838,
FT                                ECO:0000269|PubMed:10999800}.
FT                                /FTId=VAR_013111.
FT   VARIANT     224    224       L -> H (in dbSNP:rs9332963).
FT                                /FTId=VAR_059792.
FT   VARIANT     224    224       L -> M (in dbSNP:rs9332963).
FT                                /FTId=VAR_037585.
FT   VARIANT     227    227       R -> Q (in micropenis; increased affinity
FT                                for testosterone; increased affinity for
FT                                NADPH; decreased Vmax; dbSNP:rs9332964).
FT                                {ECO:0000269|PubMed:10898110,
FT                                ECO:0000269|PubMed:12843198}.
FT                                /FTId=VAR_037586.
FT   VARIANT     228    228       A -> T (in PPSH).
FT                                {ECO:0000269|PubMed:9843052}.
FT                                /FTId=VAR_013112.
FT   VARIANT     231    231       H -> R (in PPSH).
FT                                {ECO:0000269|PubMed:9745434}.
FT                                /FTId=VAR_013113.
FT   VARIANT     234    234       F -> L (increased affinity for
FT                                testosterone; increased affinity for
FT                                NADPH; decreased Vmax; no effect on
FT                                affinity for testosterone when associated
FT                                with L-89; increased affinity for NADPH
FT                                when associated with L-89; decreased Vmax
FT                                when associated with L-89).
FT                                {ECO:0000269|PubMed:10898110}.
FT                                /FTId=VAR_077552.
FT   VARIANT     235    235       Y -> F (in PPSH).
FT                                {ECO:0000269|PubMed:16181229}.
FT                                /FTId=VAR_025853.
FT   VARIANT     245    245       S -> Y (in PPSH).
FT                                {ECO:0000269|PubMed:10718838}.
FT                                /FTId=VAR_013133.
FT   VARIANT     246    246       R -> Q (in PPSH; dbSNP:rs9332967).
FT                                {ECO:0000269|PubMed:10718838,
FT                                ECO:0000269|PubMed:16181229}.
FT                                /FTId=VAR_013134.
FT   VARIANT     246    246       R -> W (in PPSH).
FT                                {ECO:0000269|PubMed:1522235,
FT                                ECO:0000269|PubMed:15528927,
FT                                ECO:0000269|PubMed:15770495,
FT                                ECO:0000269|PubMed:8626825}.
FT                                /FTId=VAR_005609.
SQ   SEQUENCE   254 AA;  28393 MW;  E65A19C8600DED05 CRC64;
     MQVQCQQSPV LAGSATLVAL GALALYVAKP SGYGKHTESL KPAATRLPAR AAWFLQELPS
     FAVPAGILAR QPLSLFGPPG TVLLGLFCVH YFHRTFVYSL LNRGRPYPAI LILRGTAFCT
     GNGVLQGYYL IYCAEYPDGW YTDIRFSLGV FLFILGMGIN IHSDYILRQL RKPGEISYRI
     PQGGLFTYVS GANFLGEIIE WIGYALATWS LPALAFAFFS LCFLGLRAFH HHRFYLKMFE
     DYPKSRKALI PFIF
//
